Devonian Health Group Inc. (DVHGF)
USD 0.13
(-6.29%)
USD 0.13
(-6.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 892.34 Thousand CAD | 59.06% |
| 2022 | 561.01 Thousand CAD | 332.88% |
| 2021 | -240.9 Thousand CAD | -243.57% |
| 2020 | -70.11 Thousand CAD | -102.25% |
| 2019 | 3.11 Million CAD | 1131.97% |
| 2018 | 252.75 Thousand CAD | 191.4% |
| 2017 | -276.54 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 516.05 Thousand CAD | 8.6% |
| 2024 Q2 | 701.99 Thousand CAD | 36.03% |
| 2024 Q3 | 1.17 Million CAD | 78.34% |
| 2023 Q3 | 140.65 Thousand CAD | 8.38% |
| 2023 Q4 | 475.17 Thousand CAD | 237.83% |
| 2023 FY | 892.34 Thousand CAD | 59.06% |
| 2023 Q1 | 146.73 Thousand CAD | -46.29% |
| 2023 Q2 | 129.77 Thousand CAD | -11.56% |
| 2022 Q4 | 273.22 Thousand CAD | -2.71% |
| 2022 Q3 | 280.83 Thousand CAD | 1826.29% |
| 2022 FY | 561.01 Thousand CAD | 332.88% |
| 2022 Q2 | 14.57 Thousand CAD | 291.28% |
| 2022 Q1 | -7622.00 CAD | 90.36% |
| 2021 Q1 | -3378.00 CAD | 99.75% |
| 2021 Q2 | -52.87 Thousand CAD | -1465.25% |
| 2021 Q3 | -105.56 Thousand CAD | -99.66% |
| 2021 FY | -240.9 Thousand CAD | -243.57% |
| 2021 Q4 | -79.08 Thousand CAD | 25.09% |
| 2020 Q4 | -1.35 Million CAD | -429.3% |
| 2020 FY | -70.11 Thousand CAD | -102.25% |
| 2020 Q3 | 410.22 Thousand CAD | -1.72% |
| 2020 Q2 | 417.42 Thousand CAD | -7.87% |
| 2020 Q1 | 453.1 Thousand CAD | -74.32% |
| 2019 Q3 | 2273.00 CAD | -99.71% |
| 2019 Q4 | 1.76 Million CAD | 77517.73% |
| 2019 FY | 3.11 Million CAD | 1131.97% |
| 2019 Q1 | 575.64 Thousand CAD | 651.98% |
| 2019 Q2 | 771.72 Thousand CAD | 34.06% |
| 2018 Q3 | 357.04 Thousand CAD | 0.0% |
| 2018 Q4 | -104.28 Thousand CAD | -129.21% |
| 2018 FY | 252.75 Thousand CAD | 191.4% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | -276.54 Thousand CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1062.493% |
| CSL Limited | 7.56 Billion USD | 99.988% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 94.051% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -28666.634% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 92.377% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.251% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 2713.004% |
| Mesoblast Limited | -35.16 Million USD | 102.537% |
| Marizyme, Inc. | 457.7 Thousand USD | -94.961% |
| Genus plc | 178.7 Million USD | 99.501% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -117.557% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 8212.191% |
| ContraFect Corporation | -154 Thousand USD | 679.442% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1884.682% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -962.29 Thousand USD | 192.73% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 330.281% |
| MultiCell Technologies, Inc. | 49.32 USD | -1809188.321% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 97.784% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1724.828% |
| Q BioMed Inc. | -8988.00 USD | 10028.138% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 96.842% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 5885.406% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1174.773% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 818.176% |
| SQZ Biotechnologies Company | 9.79 Million USD | 90.889% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 18119.81% |
| Arch Therapeutics, Inc. | -2439.00 USD | 36686.347% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1257.627% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -535.118% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.595% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -1334.032% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1015.081% |
| GB Sciences, Inc. | -624.00 USD | 143103.365% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 1137.268% |
| argenx SE | 1.1 Billion USD | 99.919% |
| HST Global, Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 429110.096% |
| Enzolytics Inc. | 30.7 Thousand USD | -2805.891% |
| Resverlogix Corp. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -84.967% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 103.459% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 97.988% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 178.168% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 273.435% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -44.536% |
| ONE Bio Corp. | 20.12 Million USD | 95.566% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.782% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 10176.118% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 1164.224% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 241.61% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 9.68% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 90.715% |
| BioStem Technologies, Inc. | 15.42 Million USD | 94.215% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 7639.848% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1949.066% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -405.404% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -405.404% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 34.249% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 3177.038% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -98.279% |
| SYBLEU INC | 11.69 Thousand USD | -7529.455% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 379.287% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 80.635% |
| Bioxytran, Inc. | -8285.00 USD | 10870.561% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 339.234% |
| Neutra Corp. | 14.33 Thousand USD | -6124.911% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 1188.221% |
| PureTech Health plc | -1.6 Million USD | 155.667% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 189.124% |
| IXICO plc | 3.27 Million USD | 72.711% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 228.579% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 149.824% |
| CSL Limited | 7.7 Billion USD | 99.988% |
| Cellectis S.A. | 18 Thousand USD | -4857.45% |